About: Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $5.42 (-2.08%)
SVRANASDAQSavara Inc
Savara Inc share price
SVRA price activity
Último preço
$ 5,420
Variação (24h)
-0,12 USD (-2,08%)
Volume
1.10M
Volume (média 4 sem.)
-
Abertura
$ 5,48
Variação do dia
$ 5,37 - $ 5,57
Fechamento anterior
$ 5,53
Último negócio
09 Sep, 8:14 pm GMT+0
Atrasado
09 Sep, 8:14 pm GMT+0
SVRA price performance
Atrasado
09 Sep, 8:14 pm GMT+0
quote.marketSignals